Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Opaganib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RedHill Biopharma Publishes Opaganib Weight Loss & Diabetes Data
    RedHill Biopharma Publishes Opaganib Weight Loss & Diabetes Data

    16 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-biopharmas-positive-opaganib-weight-loss--diabetes-data-published-signals-potential-100b-market-disruption-302430184.html

    PR NEWSWIRE
    16 Apr 2025
    Share Share
    RedHill Starts Ph 2 of Opaganib & Darolutamide in Prostate Cancer
    RedHill Starts Ph 2 of Opaganib & Darolutamide in Prostate Cancer

    04 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-initiation-of-phase-2-study-of-opaganib-and-darolutamide-in-advanced-prostate-cancer-302367315.html

    PR NEWSWIRE
    04 Feb 2025
    Share Share
    RedHill's Opaganib Confirmed as Radioprotective in GI-ARS Study
    RedHill's Opaganib Confirmed as Radioprotective in GI-ARS Study

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/radioprotective-activity-of-redhills-opaganib-for-gi-ars-confirmed-in-new-rncpniaid-study---discussions-ongoing-with-us-government-on-advanced-development-302327260.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    RedHill's Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma
    RedHill's Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma

    26 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-opaganib-granted-orphan-drug-designation-by-the-fda-for-childhood-cancer-neuroblastoma-302230324.html

    PR NEWSWIRE
    26 Aug 2024
    Share Share
    RedHill Announces Positive Obesity and Diabetes Results with Opaganib
    RedHill Announces Positive Obesity and Diabetes Results with Opaganib

    19 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-positive-obesity-and-diabetes-results-with-opaganib-302225187.html

    PR NEWSWIRE
    19 Aug 2024
    Share Share
    RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040
    RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inhibitors-valid-through-2040-302161731.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share